Neurodegenerative Drug Development Summit 2020
Previously the World CNS Summit, the Neurodegenerative Drug Development Summit returned to Boston to host over 150 neurodegeneration experts to enable them to overcome their translational challenges and successfully translate into the clinic.
Dedicated to industry challenges, with a focus on what’s new in neurodegeneration clinical progress and the latest technologies, across 34 case-study-driven scientific presentations, 4 interactive workshops and 2 parallel tracks of learning, this meeting provided a platform to:
|Deepen your biological understanding of neurodegeneration and awareness of emerging targets for more promising target identification and selection|
|Mitigate for shortcomings in preclinical models to confidently translate into clinical development|
|Review neurodegenerative biomarker advances that will improve scale sensitivity and clinical practicality for monitoring disease progression|
|Discover digital developments for their successful integration into clinical settings for earlier diagnosis|
|Explore clinical trial design for homogeneous, rapidly progressing patient populations allowing for shorter, less expensive trials with more immediate benefit to patients and attractiveness to payers|
|Hear pharmaceutical investment strategies and business models to financially de-risk neurodegenerative drug development|
|Genetic profiling of patients to manage clinical heterogeneity for patient stratification|
With its most discussion-led format yet, with 7 panel discussions, 2 audience discussions, a dedicated networking session and the Scientific Poster session, Neurodegenerative Drug Development provides unrivalled networking opportunities for you to catch up with friendly faces and make new connections to establish future partnerships.